In the latest trading session, 0.88 million Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) shares changed hands as the company’s beta touched 1.29. With the company’s most recent per share price at $1.60 changing hands around $0.0 or -0.31% at last look, the market valuation stands at $576.58M. LXRX’s current price is a discount, trading about -133.12% off its 52-week high of $3.73. The share price had its 52-week low at $0.92, which suggests the last value was 42.5% up since then. When we look at Lexicon Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 2.78 million shares, with the 3-month average coming to 2.87 million.

Analysts gave the Lexicon Pharmaceuticals Inc (LXRX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.67. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended LXRX as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Lexicon Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.16.

Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) trade information

Instantly LXRX was in red as seen in intraday trades today. With action 0.95%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 4.25%, with the 5-day performance at 0.95% in the green. However, in the 30-day time frame, Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) is -11.39% down. Looking at the short shares, we see there were 26.63 million shares sold at short interest cover period of 11.0 days.

Lexicon Pharmaceuticals Inc (LXRX) estimates and forecasts

Data shows that the Lexicon Pharmaceuticals Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -30.04% over the past 6 months, a 12.66% in annual growth rate that is considerably lower than the industry average of 17.70%. Year-over-year growth is forecast to reach 1,261.30% up from the last financial year.

Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 5.22M. 6 analysts are of the opinion that Lexicon Pharmaceuticals Inc’s revenue for the current quarter will be 8.41M. The company’s revenue for the corresponding quarters a year ago was 162k and 702k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 3,122.20%. The estimates for the next quarter sales put growth at 1,098.00%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 6.80%. The 2024 estimates are for Lexicon Pharmaceuticals Inc earnings to increase by 14.47%.

LXRX Dividends

Lexicon Pharmaceuticals Inc is expected to release its next quarterly earnings report on 2024-Nov-06.

Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 1.15% of Lexicon Pharmaceuticals Inc shares while 79.24% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 80.16%. There are 79.24% institutions holding the Lexicon Pharmaceuticals Inc stock share, with ARTAL GROUP S.A. the top institutional holder. As of 2024-06-30, the company held 71.3555% of the shares, roughly 175.1 million LXRX shares worth $294.17 million.

FMR LLC holds the second largest percentage of outstanding shares, with 15.7656% or 38.69 million shares worth $64.99 million as of 2024-06-30.